Spots Global Cancer Trial Database for Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
Official Title: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer : A Phase III, Open Label, Randomized Controlled Trial
Study ID: NCT05430399
Study Description
Brief Summary: It is a phase III trial to explore the efficacy and safety of utidelone versus docetaxel in HER2-negative locally advanced or metastatic breast cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Shusen Wang, Guangzhou, Gangdong, China
Hunan Cancer Hospital, Hunan, Hunan, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
